Feasibility and safety of granulocytapheresis in Crohn’s disease: A prospective cohort study

G Bresci ¹, A Romano, A Mazzoni, F Scatena, E Altomare, A Capria, R Sacco, Gastroenterol Clin Biol. 2010 Dec;34(12):682-6.

No major complications were observed. At the end of GCAP, 19 (63.3%) patients showed a clinical remission: 10 (62.5%) in group A versus 9 (64.2%) in group B. At 6 months, 16 (53.3%) of the cases had maintained remission: 9 (56.2%) in group A versus 7 (50.0%) in group B. At 9 months, 13 (43.3%) patients had maintained remission: 7 (43.7%) in group A versus 6 (42.8%) in group B. At 12 months, 12 (40%) patients were still in clinical remission: 7 (43.7%) in group A versus 5 (35.7%) in group B. Risk of relapse was not related to disease location. The procedure was well tolerated and feasible in an important percentage of Crohn’s disease patients.

https://pubmed.ncbi.nlm.nih.gov/21075574/

https://www.researchgate.net/publication/47791004_Feasibility_and_safety_of_granulocytapheresis_in_Crohn’s_disease_A_prospective_cohort_study